Table 1.
Demographics of the overall population, and by age older than 55 years and by sex. p-values < 0.05 are highlighted in bold. ABC: abacavir; AIDS: adquired immune deficency syndrome; ART: antiretroviral therapy; HBV: hepatitis B virus; HCV: hepatitis C virus; INSTI: integrase strand transfer inhibitors; NNRTI: non-nucleosidic reverse transcriptase inhibitors; PI: protease inhibitors; TDF: tenofovir disoproxil fumarate; TAF: tenofovir alafenamide fumarate.
| Overall | Over 55 Years | Under 55 Years | p | Female | Male | p | |
|---|---|---|---|---|---|---|---|
| n = 164 | n = 106 | n = 58 | n = 48 | n = 116 | |||
| m/# (IQR/%) | m/# (IQR/%) | m/# (IQR/%) | m/# (IQR/%) | m/# (IQR/%) | |||
| Sex | |||||||
| Female | 48 (29.3%) | 27 (25.5%) | 21 (36.2%) | 0.156 | 48 (100%) | 0 (0%) | <0.001 |
| Male | 116 (70.7%) | 79 (74.5%) | 37 (63.8%) | 0 (0%) | 116 (100%) | ||
| Age (years) | 57 (47–61) | 59 (57–64) | 41 (37–48) | <0.001 | 56 (46–58) | 57 (47–62) | 0.0893 |
| Smoking (yes) | 108 (65.9%) | 68 (64.2%) | 40 (69.0%) | 0.607 | 28 (58.3%) | 80 (69.0%) | 0.209 |
| Time from HIV-1 diagnosis (years) | 16 (9.5–22) | 19 (12–24) | 12 (6.0–15) | <0.001 | 19 (10–24) | 15 (8.0–21) | 0.113 |
| History of AIDS diagnosis (yes) | 55 (33.5%) | 40 (37.7%) | 15 (25.9%) | 0.166 | 15 (31.3%) | 40 (34.5%) | 0.72 |
| HBV co-infection (yes) | 12 (7.3%) | 8 (7.5%) | 4 (6.9%) | 1 | 2 (4.2%) | 10 (8.6%) | 0.512 |
| Former HCV infection (yes) | 18 (11.0%) | 15 (14.2%) | 3 (5.2%) | 0.116 | 8 (16.7%) | 10 (8.6%) | 0.17 |
| HIV-1-related non-AIDS comorbidities (≥1) | 98 (59.8%) | 73 (68.9%) | 25 (43.1%) | 0.002 | 30 (62.5%) | 68 (58.6%) | 0.727 |
| How many | 1 (0–1) | 1 (0–2.0) | 0 (0–1) | <0.001 | 1 (0–1) | 1 (0–1) | 0.591 |
| Osteoporosis | 27 (16.5%) | 23 (21.7%) | 4 (6.9%) | 0.015 | 8 (16.7%) | 19 (16.4%) | 1 |
| Type 2 Diabetes | 12 (7.3%) | 10 (9.4%) | 2 (3.4%) | 0.217 | 4 (8.3%) | 8 (6.9%) | 0.748 |
| Hypertension | 32 (19.5%) | 26 (24.5%) | 6 (10.3%) | 0.038 | 8 (16.7%) | 24 (20.7%) | 0.667 |
| Major Cardiovascular events | 12 (7.3%) | 12 (11.3%) | 0 (0%) | 0.008 | 1 (2.1%) | 11 (9.5%) | 0.183 |
| Other than ART co-medications | |||||||
| ≥1 | 69 (42.1%) | 49 (46.2%) | 20 (34.5%) | 0.186 | 26 (54.2%) | 43 (37.1%) | 0.056 |
| ≥2 | 41 (25.0%) | 33 (31.1%) | 8 (13.8%) | 0.015 | 12 (25.0%) | 29 (25.0%) | 1 |
| Pre-switch ART regimen | |||||||
| INSTI | 38 (23.2%) | 23 (21.7%) | 15 (25.9%) | 9 (18.8%) | 29 (25.0%) | ||
| NNRTI | 20 (12.2%) | 11 (10.4%) | 9 (15.5%) | 0.545 | 3 (6.3%) | 17 (14.7%) | 0.134 |
| PI | 99 (60.4%) | 68 (64.2%) | 31 (53.4%) | 32 (66.7%) | 67 (57.8%) | ||
| PI+INSTI | 7 (4.3%) | 4 (3.8%) | 3 (5.2%) | 4 (8.3%) | 3 (2.6%) | ||
| TDF-based backbone | 95 (57.9%) | 67 (63.2%) | 28 (48.3%) | 0.071 | 22 (45.8%) | 73 (62.9%) | 0.056 |
| TAF-based backbone | 49 (29.9%) | 26 (24.5%) | 23 (39.7%) | 0.051 | 15 (31.3%) | 34 (29.3%) | 0.852 |
| ABC-based backbone | 5 (3.0%) | 3 (2.8%) | 2 (3.4%) | 1 | 4 (8.3%) | 1 (.9%) | 0.026 |
| Boosted-regimen | 124 (75.6%) | 79 (74.5%) | 45 (77.6%) | 0.708 | 40 (83.3%) | 84 (72.4%) | 0.165 |
| Dual therapy | 10 (6.1%) | 8 (7.5%) | 2 (3.4%) | 0.497 | 4 (8.3%) | 6 (5.2%) | 0.481 |
| Reason to switch | |||||||
| Adherence | 4 (2.4%) | 3 (2.8%) | 1 (1.7%) | 0.536 | 3 (6.3%) | 1 (0.9%) | 0.279 |
| Adverse events | 1 (0.6%) | 1 (0.9%) | 0 (0%) | 0 (0%) | 1 (0.9%) | ||
| Proactive | 15 (9.1%) | 7 (6.6%) | 8 (13.8%) | 5 (10.4%) | 10 (8.6%) | ||
| Simplification | 110 (67.1%) | 71 (67.0%) | 39 (67.2%) | 32 (66.7%) | 78 (67.2%) | ||
| Toxicity | 34 (20.7%) | 24 (22.6%) | 10 (17.2%) | 8 (16.7%) | 26 (22.4%) |